AMNIOX Medical Introduces RESPINA at NASS 2017

ORLANDO, Fla.--(BUSINESS WIRE)-- Amniox Medical, a TissueTech company, highlighted the introduction of RESPINA its cryopreserved umbilical cord/amniotic membrane matrix at the North American Spine Society’s (NASS) annual meeting in Orlando, FL, October 25 - 27.

AMNIOX Medical’s proprietary amniotic membrane technology has been clinically proven in a randomized controlled trial to enhance surgical outcomes in microdiscectomy, improving function and reducing both pain and the incidence of recurrent herniation¹. The umbilical cord/amniotic membrane tissue, processed through CRYOTEK technology, offers a simple solution for physicians to support restorative healing and improve procedural benefits.

RESPINA will also be recognized as the 2017 Orthopedics This Week Spine Technology Award recipient in the biomaterials and biologics category at NASS.

“Spine Tech Awards recognize excellence, innovation and the advancement of spinal care,” said Tom Dugan, AMNIOX Medical CEO. “This recognition underscores the clinical evidence and economic benefits that continue to accumulate in support of the use of our cryopreserved placental tissue with its decades long track record in ocular surgery. The restorative healing proven in microdiscectomy has encouraged us to explore other promising applications in spine and orthopedics. This is a simple, natural, safe, and proven platform technology that we are excited to launch into spine.”

Microdiscectomy is a minimally invasive procedure with a small incision required to remove the herniated lumbar disc material. This removal relieves pressure on the nearby spinal cord and nerves. The biological components of RESPINA have been demonstrated to modulate local inflammation and minimize the potential for the formation of scar tissue and adhesions.

To learn more about AMNIOX Medical and RESPINA, NASS 2017 attendees may visit booth 237.

About Amniox Medical, Inc.

Founded in 2011 to serve the orthopedic and wound care markets, AMNIOX Medical is dedicated to developing and marketing regenerative therapies processed from umbilical cord and amniotic membrane utilizing its proprietary CRYOTEK technology. This process has been proven to preserve the innate biological and structural properties of the matrix, which can then be transplanted to adult wound and surgical environments. AMNIOX Medical procures its tissue through elective donation following healthy live birth via Cesarean section. Thorough donor screening is performed to ensure safety of its products. For additional information, please visit http://www.amnioxmedical.com.

About TissueTech, Inc.

TissueTech, Inc., the parent company of AMNIOX Medical, Inc. and BioTissue, Inc., pioneered the advancement and clinical application of regenerative, amniotic tissue-based products. AMNIOX Medical develops and markets products for use in the musculoskeletal and wound care markets; BioTissue develops and markets products for the ophthalmology and optometry markets. The National Institutes of Health (NIH) has supported TissueTech’s research with more than 25 continuous years of research grants. Since the company’s inception, clinicians have performed more than 300,000 human implants of the company’s products and published more than 300 peer-reviewed studies supporting its technology platform. The Company’s first product, AmnioGraft^®, is the only tissue graft designated by the FDA as homologous for promoting ophthalmic wound healing while suppressing scarring and inflammation.

¹ Anderson, D. Greg; Popov, Victor; Raines, Andrew L., Ph.D., Connell, Julie PhD. “Cryopreserved Amniotic Membrane Improves Clinical Outcomes Following Microdiscectomy.” Clinical Spine Surgery, 26 May 2017, http://journals.lww.com/jspinaldisorders/Abstract/publishahead/Cryopreserved_Amniotic_Membrane_Improves_Clinical.99629.aspx

View source version on businesswire.com: http://www.businesswire.com/news/home/20171026005088/en/